25579575,25489169,23428096,22555953,21239176,20174454,20096141,19038776,19008196,18846074,18806783[uid] - Search Results

Year	Number of Results
2008	2
2009	3
2010	1
2011	1
2012	1
2013	1
2014	1
2015	1
2024	0

1

An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor.

Sinha C, Nischal A, Bandaru S, Kasera P, Rajput A, Nayarisseri A, Khattri S. Sinha C, et al. Curr Top Med Chem. 2015;15(1):65-72. doi: 10.2174/1568026615666150112114337. Curr Top Med Chem. 2015. PMID: 25579575

2

Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.

Sinha C, Nischal A, Pant KK, Bandaru S, Nayarisseri A, Khattri S. Sinha C, et al. Bioinformation. 2014 Oct 30;10(10):611-6. doi: 10.6026/97320630010611. eCollection 2014. Bioinformation. 2014. PMID: 25489169 Free PMC article.

3

Harnessing the therapeutic potential of host antiviral restriction factors that target HIV.

Sloan RD, Wainberg MA. Sloan RD, et al. Expert Rev Anti Infect Ther. 2013 Jan;11(1):1-4. doi: 10.1586/eri.12.146. Expert Rev Anti Infect Ther. 2013. PMID: 23428096 No abstract available.

4

Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.

Ali A, Wang J, Nathans RS, Cao H, Sharova N, Stevenson M, Rana TM. Ali A, et al. ChemMedChem. 2012 Jul;7(7):1217-29. doi: 10.1002/cmdc.201200079. Epub 2012 May 3. ChemMedChem. 2012. PMID: 22555953 Free PMC article.

5

APOBEC3G: a double agent in defense.

Smith HC. Smith HC. Trends Biochem Sci. 2011 May;36(5):239-44. doi: 10.1016/j.tibs.2010.12.003. Epub 2011 Jan 14. Trends Biochem Sci. 2011. PMID: 21239176 Free PMC article.

6

Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Hultquist JF, Harris RS. Hultquist JF, et al. Future Virol. 2009 Nov 1;4(6):605. doi: 10.2217/fvl.09.59. Future Virol. 2009. PMID: 20174454 Free PMC article.

7

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Albin JS, Harris RS. Albin JS, et al. Expert Rev Mol Med. 2010 Jan 22;12:e4. doi: 10.1017/S1462399409001343. Expert Rev Mol Med. 2010. PMID: 20096141 Free PMC article. Review.

8

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH. Malim MH. Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Philos Trans R Soc Lond B Biol Sci. 2009. PMID: 19038776 Free PMC article. Review.

9

APOBEC3G: an intracellular centurion.

Chiu YL, Greene WC. Chiu YL, et al. Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Philos Trans R Soc Lond B Biol Sci. 2009. PMID: 19008196 Free PMC article. Review.

10

Enhancing immunity to HIV through APOBEC.

Harris RS. Harris RS. Nat Biotechnol. 2008 Oct;26(10):1089-90. doi: 10.1038/nbt1008-1089. Nat Biotechnol. 2008. PMID: 18846074 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year